- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05663372
Bioequivalence Study of Test and Reference 50 mg Eplerenone Film-coated Tablets in Healthy Volunteers
December 15, 2022 updated by: Darnitsa Pharmaceutical Company
Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Efez 50 mg Eplerenone Film-coated Tablets Versus INSPRA® 50 mg Eplerenone Film-coated Tablets, in Healthy Adult Male and Female Subjects Under Fasting Conditions
This study is a comparative bioavailability study performed to assess bioequivalence between Test medicinal product (Efez 50 mg eplerenone film-coated tablets manufactured by PrJSC "Pharmaceutical firm "Darnitsa", Ukraine) and Reference medicinal product (marketed medicinal product INSPRA® 50 mg eplerenone film-coated tablets, Marketing Authorisation Holder: Pfizer Europe MA EEIG, Belgium) in healthy volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amman, Jordan, 11190
- ACDIMA Center for Bioequivalence and Pharmaceutical Studies
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject is Caucasian & aged between eighteen to fifty years (18 - 50), both inclusive.
- The subject is within the limits for his height & weight as defined by the body mass index range (18.5 - 30.0 Kg/m2).
- The subject is willing to undergo the necessary pre- & post- medical examinations set by this study.
- The results of medical history, physical examination, vital signs & conducted medical laboratory tests are normal as determined by the clinical investigator.
- The subject tested negative for hepatitis B (HBsAg), hepatitis C (HCVAb), human immunodeficiency virus (HIVAb) & COVID-19 (PCR) test.
- There is no evidence of psychiatric disorder, antagonistic personality, and poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
- The subject is able to understand and willing to sign the informed consent form.
- For female subjects: a negative pregnancy test must be confirmed, and if sexually active, at least 4 weeks of highly effective contraceptive method must be used prior to IMP administration and throughout the study progress until last visit; highly effective methods comprise hormonal contraceptives, intrauterine devices IUDs, sexual abstinence or vasectomized partner (success of vasectomy was medically proven). For subjects using a hormonal contraceptive method, a barrier form of contraception should be combined with the hormonal contraception.
- The subject has normal cardiovascular system & ECG recording.
- The subject kidney and liver (AST & ALT enzymes) functions tests are within normal range.
- The subject blood pressure is ≥ 110/70 mmHg before dosing.
- The subject has normal serum creatinine and potassium levels on screening (before 24 hours of admission).
- The subject HbA1c test result is within normal range.
Exclusion Criteria:
- Subject is a smoker or an ex-smoker with a non-smoking history of less than 6 months.
- The subject has suffered an acute illness one week before dosing.
- The subject has a history of or concurrent abuse of alcohol.
- The subject has a history of or concurrent abuse of illicit drugs.
- The subject has a history of hypersensitivity and/or contraindications to the study drug and any related compounds.
- The subject has been hospitalized within three months before the study or during the study.
- The subject is on special diet (for example subject is vegetarian).
- The subject has consumed caffeine or xanthine containing beverages or foodstuffs within two days before dosing and until 36 hours after dosing in all study periods.
- The subject has taken a prescription medication within two weeks or even an over the counter product (OTC) within one week before dosing in each study period and any time during the study, unless otherwise judged acceptable by the clinical investigator.
- The subject has taken grapefruit containing beverages or foodstuffs within seven (7) days before first dosing and any time during the study.
- The subject has been participating in any clinical study (e.g. pharmacokinetics, bioavailability and bioequivalence studies) within the last 80 days prior to the present study.
- The subject has donated blood within 80 days before first dosing.
- The subject has a history or presence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinal, immunological, dermatological, neurological, musculoskeletal or psychiatric diseases.
- The subject has consumed drugs or foodstuffs that may affect pharmacological or pharmacokinetic properties of eplerenone (for example: strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir), potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene), ACE inhibitors and angiotensin II receptor antagonists, lithium or NSAIDs) two weeks before dosing, during the study and two weeks after dosing.
- Pregnant; with positive serum pregnancy test or breast-feeding female subjects.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Efez (Test)
A single oral dose of the test product Efez 50 mg eplerenone film-coated tablets.
|
Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
|
Active Comparator: INSPRA®
A single oral dose of the reference product INSPRA® 50 mg eplerenone film-coated tablets.
|
Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax)
Time Frame: Blood sampling for pharmacokinetic analysis covered up to 36 hours post-dose.
|
The Cmax value is based on the eplerenone plasma concentration.
|
Blood sampling for pharmacokinetic analysis covered up to 36 hours post-dose.
|
Area under the concentration-time curve from time zero to the last quantifiable concentration (t)
Time Frame: Blood sampling for pharmacokinetic analysis covered up to 36 hours post-dose.
|
The AUC0-t is the area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (t) and is based on the eplerenone plasma concentration.
|
Blood sampling for pharmacokinetic analysis covered up to 36 hours post-dose.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 7, 2021
Primary Completion (Actual)
December 28, 2021
Study Completion (Actual)
December 28, 2021
Study Registration Dates
First Submitted
December 15, 2022
First Submitted That Met QC Criteria
December 15, 2022
First Posted (Estimate)
December 23, 2022
Study Record Updates
Last Update Posted (Estimate)
December 23, 2022
Last Update Submitted That Met QC Criteria
December 15, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPL01-E
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on Efez 50 mg eplerenone film-coated tablets
-
AbbottRecruitingFunctional DyspepsiaMalaysia, Armenia
-
Valenta Pharm JSCCompletedInfluenza, Human | Common Cold | Acute Respiratory InfectionRussian Federation
-
Future University in EgyptCompleted
-
Fundacion Clinic per a la Recerca BiomédicaActive, not recruiting
-
Valenta Pharm JSCCompletedInfluenza, Human | Common Cold | Acute Respiratory InfectionRussian Federation
-
SandozCompleted
-
SandozCompleted
-
Reseach Laboratory of Clinical and Experimental...Société Arabe des Industries Pharmaceutiques SAIPH - Tunisia; Centre National...CompletedFed ConditionsTunisia
-
Boehringer IngelheimCompleted
-
Reseach Laboratory of Clinical and Experimental...La Société Arabe des Industries Pharmaceutiques-Tunisie; Centre National Chalbi...Completed